User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

6074

Interactions with Platform & by Email *

INTERACTIONS

972

Unique # Participated *

PARTICIPANTS

182

Responses Validated *

VALIDATIONS

39

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Tuberculosis: A Reality Check.....II-1
Evolutionary Battle Against the TB Bug Drives the Future of the Market.....II-1
TB Prevalence Statistics: A Current Review.....II-1
1$100
   Table 1: Worldwide Prevalence of TB Cases (in 000s) by Region for the Year (2007) (includes corresponding Graph/Chart).....II-2

Table 2: Worldwide Incidence of TB Cases (in 000s) by Region for the Year (2007) (includes corresponding Graph/Chart).....II-2
1$300
   Table 3: Worldwide TB Mortality (2009): Breakdown of Number of TB Deaths (in '000s) by Region (includes corresponding Graph/Chart).....II-3
Effectiveness of Current TB Management Strategies.....II-3
1$300
   Table 4: Currently Established TB First-Line Drugs, & Fixed-Dose Combination Drugs.....II-4

Table 5: Currently Established TB Second- Line Drugs.....II-4
Renewed Interest in TB Drugs Development.....II-4
1$300
   A Peek into the Current Drug Development Pipeline.....II-51$100
   TB Drugs in Pipeline as of the Year 2008.....II-6
The Importance of Public-Private Partnerships (PPP).....II-6
1$100
   The Promise of New Therapeutic Advancements.....II-7
Nano Drug Delivery Offers a Ray of Hope.....II-7
1$100
   What’s The Need of the Hour?.....II-8
Moving Research to Market .....II-8
1$100
   Challenges in Drug Development.....II-9
Antidotes.....II-9
Recalibration of Drug Arsenal Against Resistant & HIV Co-Infected TB Cases.....II-9
1$100
   TB Research in Dire Need of Funding.....II-10
Table 6: Global Tuberculosis R&D Investment for the years 2005 through 2008 (In US$ Million) (includes corresponding Graph/Chart).....II-10
1$300
   Table 7: Worldwide TB Drugs Market (2007): Percentage Share Breakdown of Funding by Donor (includes corresponding Graph/Chart).....II-11

Table 8: Worldwide TB R&D Funding (2008): Percentage Share Breakdown of Allocated Funds by Area of Research (includes corresponding Graph/Chart).....II-11
1$300
   Table 9: Global Tuberculosis R&D Investment: Breakdown of R&D Sponsors for the year 2008 (In US$ Million).....II-121$300
   Table 10: Global Tuberculosis R&D Investment (2008): Percentage Share Breakdown of Funds by Donor Type (includes corresponding Graph/Chart).....II-13
Bottleneck in Logistics Need to be Ironed Out.....II-13
1$300
   Other Trends & Issues.....II-14
The State of Research Funding Amidst the Recession .....II-14
Growth in Drug Resistant TB Cases Drive Second-Line Therapeutic Drugs Market.....II-14
HIV Infections: A Major Catalyst in Global Increase of TB.....II-14
1$100
   Pharma Companies Called Upon to Focus on TB Drug Development.....II-15
High Prevalence in Developing Countries offer a Strong Commercial Opportunity.....II-15
1$100
   Table 11: Prevalence of TB in High Burden Countries (2007): Percentage Share Breakdown of Prevalent Cases by Country (includes corresponding Graph/Chart).....II-161$300
   Table 12: Burden of TB Worldwide (2007): Breakdown of Number of cases of TB Prevalence (‘000s) by Country (includes corresponding Graph/Chart).....II-171$300
   Table 13: Burden of TB in High Burden Countries (2007): Breakdown of Number of Deaths (‘000s) by Country (includes corresponding Graph/Chart).....II-18
A Peek Into the Commitments Voiced by High Burden Countries.....II-18
MDR-TB on the Rise in Dragon Land.....II-18
1$300
   What’s the Chinese Government Doing About It?.....II-19
Indonesia: Pledges Support to TB Drug Research.....II-19
1$100
   South Africa Publicizes Its Commitment.....II-20
Other Statistical Findings.....II-20
Table 14: Tuberculosis Prevalence in Japan: Breakdown of Notified Patients by Age Group for the year 2006 through 2008 (includes corresponding Graph/Chart).....II-20
1$300
   Table 15: Tuberculosis Prevalence in Japan: Breakdown of Notified Patients by Gender for the year 2006 through 2008 (includes corresponding Graph/Chart).....II-21

Table 16: Tuberculosis Prevalence in Japan: Breakdown of Notified Patients by Prefecture/ Designated City for the year 2008 (includes corresponding Graph/Chart).....II-21
1$300
   Tuberculosis (TB): A Prevalent, Yet Neglected Disease.....II-22
Latent TB Infection.....II-22
Active TB Infection.....II-22
A Peek Into the Bacteria Causing the Disease .....II-22
1$100
   Types of Tuberculosis.....II-23
Pulmonary Tuberculosis.....II-23
Extra Pulmonary Tuberculosis.....II-23
Diagnosis of TB.....II-23
1$100
   Prevention of TB.....II-24
The Cure.....II-24
1$100
   The DOTS Program: A Review.....II-251$100
   TB Drugs.....II-26
First line Drugs.....II-26
Isoniazid.....II-26
Mode of Action & Dosage.....II-26
1$100
   Side Effects.....II-27
Rifampin.....II-27
Mode of Action.....II-27
1$100
   Side Effects.....II-28
Pyrazinamide.....II-28
Dosage.....II-28
Mode of Action.....II-28
Side Effects.....II-28
1$100
   Ethambutol.....II-29
Mode of Action.....II-29
Side Effects.....II-29
Streptomycin.....II-29
1$100
   Second Line Drugs.....II-30
Aminoglycosides.....II-30
Mode of Action.....II-30
Fluoroquinolones.....II-30
1$100
   Moxifloxacin (MXF).....II-311$100
   Cycloserine.....II-32
p-aminosalicylic acid (PAS or P).....II-32
1$100
   Across America Financial Services Acquires Apro Bio Pharmaceutical.....II-33
Academia Sinica Inks MoU with Infectious Disease Research Institute.....II-33
TB Alliance Enters into Collaboration with Tibotec.....II-33
1$100
   Rx for Africa Inks Letter of Intent with Rusan Pharma.....II-34
Johnson & Johnson to Establish Drug Research Centre.....II-34
Anacor Inks Agreements with Two Non-profit Organizations.....II-34
1$100
   Lupin Obtains USFDA Approval.....II-35
Sequella Commence Phase IB Study for SQ109.....II-35
Regional Model TB Center Establishes New Center.....II-35
AstraZeneca to Commence Safety Studies for TB Drug Candidate.....II-35
GADD and TIM Enters into Partnership.....II-35
1$100
   NWHD to Establish New Tuberculosis Facility.....II-36
Cadila Pharmaceuticals Launches Risorine.....II-36
Merck and Eli Lilly Collaborate for TB Treatment.....II-36
Sanofi-aventis Enters into Collaboration with TB Alliance.....II-36
Summit Corp Enters into Co development Agreement with Lilly PPP.....II-36
1$100
   NITD Collaborates with TB Alliance to Discover New Anti-TB Drugs.....II-37
Ranbaxy Enters into Alliance with DBT for TB Drug Discovery and Research.....II-37
Sanofi pasteur Inks License and Research Agreement with SSI.....II-37
1$100
   Profiles of generic drug companies & pharma majors, developing TB drugs in
  collaboration with not-for profit organizations & academic institutes.....II-38
AstraZeneca (UK).....II-38
Bayer AG (Germany).....II-38
Bristol-Myers Squibb Co. (USA).....II-38
1$100
   Eli Lilly and Company (USA).....II-39
GlaxoSmithKline Plc. (UK).....II-39
Lupin Limited (India).....II-39
1$100
   Novartis AG (Switzerland).....II-40
Ranbaxy Laboratories Limited (India).....II-40
1$100
   Rusan Pharma Ltd., (India).....II-41
Rx for Africa, Inc., (USA).....II-41
Sanofi-Aventis SA (France).....II-41
1$100
   Summit Plc (UK).....II-42
Tibotec BVBA (Belgium).....II-42
Otsuka Pharmaceutical Co., Ltd. (Japan).....II-42
1$100
   Sequella, Inc., (USA).....II-43
Profiles of key non-profit organizations & academic institutes.....II-43
Global Alliance for TB Drug Development (USA).....II-43
1$100
   Research Project Pipeline of the Global Alliance for TB Drug Development As of the
  Year 2009.....II-44
1$100
   Institute of Microbiology, Chinese Academy of Sciences (China).....II-451$100
   Table 17: World Recent Past, Current & Future Market Analysis for Tuberculosis (TB) Therapeutics Analyzed with Annual Sales in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-461$300
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com